[HTML][HTML] Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …
[HTML][HTML] Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
R Sharma, E Kadife, M Myers, G Kannourakis… - Journal of Experimental …, 2021 - Springer
Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several
FGFR inhibitors are currently under clinical investigation. Resistance usually results from …
FGFR inhibitors are currently under clinical investigation. Resistance usually results from …
FGFR families: biological functions and therapeutic interventions in tumors
Q Liu, J Huang, W Yan, Z Liu, S Liu, W Fang - MedComm, 2023 - Wiley Online Library
There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When
FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and …
FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and …
[PDF][PDF] Responses to alectinib in ALK-rearranged papillary renal cell carcinoma
Approximately 10–15% of all patients with renal cell carcinoma (RCC) demonstrate papillary
histology [1]. For patients with metastatic papillary RCC (mPRCC), there is limited …
histology [1]. For patients with metastatic papillary RCC (mPRCC), there is limited …
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
M Matsuki, Y Adachi, Y Ozawa, T Kimura… - Cancer …, 2017 - Wiley Online Library
The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, plus everolimus,
a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes …
a mammalian target of rapamycin (mTOR) inhibitor, significantly improved clinical outcomes …
Ang II (Angiotensin II)–Induced FGFR1 (Fibroblast Growth Factor Receptor 1) Activation in Tubular Epithelial Cells Promotes Hypertensive Kidney Fibrosis and Injury
Z Xu, W Luo, L Chen, Z Zhuang, D Yang, J Qian… - …, 2022 - Am Heart Assoc
Background: Elevated Ang II (angiotensin II) level leads to a range of conditions, including
hypertensive kidney disease. Recent evidences indicate that FGFR1 (fibroblast growth factor …
hypertensive kidney disease. Recent evidences indicate that FGFR1 (fibroblast growth factor …
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations
HK Ho, AHL Yeo, TS Kang, BT Chua - Drug discovery today, 2014 - Elsevier
Highlights•Dysregulation of fibroblast growth factor receptor (FGFR) signaling in many
diseases prompts development of inhibitors.•Inhibitors are derived from rational design and …
diseases prompts development of inhibitors.•Inhibitors are derived from rational design and …
[HTML][HTML] Inflammatory networks in renal cell carcinoma
Simple Summary Inflammation is an important hallmark of advanced renal cell carcinoma
and plays a pivotal role in tumor progression, metastasis, and anti-cancer resistance …
and plays a pivotal role in tumor progression, metastasis, and anti-cancer resistance …
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell
carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy …
carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy …